Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hyloris Pharmaceuticals SA currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action across the entire portfolio. This action is assigned to 1 distinct examiner, indicating a concentrated prosecution effort. The portfolio is currently localized within 1 distinct art unit, suggesting a specific technical scope for the pending intellectual property.
BORI, IBRAHIM D serves as the busiest examiner for the company, currently handling 1 pending office action. This figure represents the company's active prosecution workload. Because the examiner count is 1, the prosecution strategy relies on the interactions with this specific individual. The presence of 1 distinct art unit further confirms that the current legal challenges are confined to a specific regulatory or technical niche within the Biotechnology & Pharmaceuticals field. Practitioners should note that the 1 pending office action defines the immediate procedural landscape for the portfolio. The concentration of active matters under the examiner and the art unit allows for a specialized focus during the negotiation of patent claims. This structure simplifies the administrative complexity of the prosecution process.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18827922 | AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN | BORI, IBRAHIM D | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18827922 | AQUEOUS FORMULATION COMPRISING PARACETAMOL AND IBUPROFEN | BORI, IBRAHIM D | 1629 | §103§112DP | Non-Final OA | — | Pending | Sep 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHyloris Pharmaceuticals SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ibrahim D Bori has the most, with 1 of Hyloris Pharmaceuticals SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.